Grape King Bio (TPE:1707) EBIT: NT$2,302 Mil (TTM As of Dec. 2025)


TPE:1707 Grape King Bio Ltd TPE:1707
78 GF Score
Price NT$91.00
GF Value NT$144.03
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Grape King Bio EBIT?

Grape King Bio TPE:1707 -0.11% 78 EBIT is NT$2,302 Mil as of Dec. 2025. GuruFocus rates TPE:1707 with a GF Score™ of 78/100 and a GF Value™ of NT$144.03 (Possible Value Trap). The stock has 5 warning signs investors should review.

Grape King Bio's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$803 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2,302 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Grape King Bio's annualized ROC % for the quarter that ended in Dec. 2025 was 23.79%. Grape King Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 40.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Grape King Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 20.66%.


Grape King Bio  (TPE:1707) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Grape King Bio's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=2973.64 * ( 1 - 18.1% )/( (10119.426 + 10352.778)/ 2 )
=2435.41116/10236.102
=23.79 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14489.483 - 2302.251 - ( 3262.068 - max(0, 2585.838 - 4653.644+3262.068))
=10119.426

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15738.289 - 3145.965 - ( 4277.597 - max(0, 3421.232 - 5660.778+4277.597))
=10352.778

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Grape King Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3213.004/( ( (7914.654 + max(-1142.968, 0)) + (8075.902 + max(-1998.035, 0)) )/ 2 )
=3213.004/( ( 7914.654 + 8075.902 )/ 2 )
=3213.004/7995.278
=40.19 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(409.601 + 828.547 + 133.136) - (2302.251 + 0 + 212.001)
=-1142.968

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(336.554 + 829.182 + 185.293) - (3145.965 + 0 + 203.099)
=-1998.035

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Grape King Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=2302.447/11142.453
=20.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grape King Bio EBIT Related Terms


Grape King Bio EBIT Historical Data

* Premium members only.

The historical data trend for Grape King Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grape King Bio EBIT Chart

Grape King Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,418.92 2,690.25 2,663.16 2,676.34 2,302.45

Grape King Bio Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 821.02 414.77 505.35 579.08 803.25

TPE:1707 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grape King Bio EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Grape King Bio's EV-to-EBIT falls into.


TPE:1707
78GF Score
Grape King Bio Ltd TPE:1707
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grape King Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2,302 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$2,302 Mil mean?
Grape King Bio (TPE:1707) has a EBIT of NT$2,302 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Grape King Bio.
Is Grape King Bio's EBIT too high?
Grape King Bio's current EBIT is NT$2,302 Mil. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's EBIT compare to ZTS and UTHR?
Grape King Bio's EBIT of NT$2,302 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Grape King Bio. Grape King Bio's current EBIT is NT$2,302 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.03, compared to a current price of NT$91.00 — trading 36.8% below its estimated fair value. The current EBIT is NT$2,302 Mil. Grape King Bio's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current EBIT is NT$2,302 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grape King Bio (TPE:1707) Overvalued in 2026?

Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued. The current stock price of NT$91.00 is trading 36.8% below its estimated GF Value™ of NT$144.03. GuruFocus considers Grape King Bio to be Possible Value Trap.

Key valuation signals for TPE:1707:

  • EBIT: NT$2,302 Mil
  • GF Value™: NT$144.03 vs. price of NT$91.00 (36.8% below fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grape King Bio Business Description

Address Jinling Road, No. 402, Section 2, Pingzhen District, Pingzhen District, Taoyuan, TWN, 324
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score

Get the complete analysis for TPE:1707

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$91.00
Price
NT$144.03
GF Value